We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Regen BioPharma Inc. has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating autoimmune diseas